US4929446A - Unit dosage form - Google Patents
Unit dosage form Download PDFInfo
- Publication number
- US4929446A US4929446A US07/183,683 US18368388A US4929446A US 4929446 A US4929446 A US 4929446A US 18368388 A US18368388 A US 18368388A US 4929446 A US4929446 A US 4929446A
- Authority
- US
- United States
- Prior art keywords
- medicament
- dosage form
- unit dosage
- sugar
- semi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 39
- 239000007788 liquid Substances 0.000 claims abstract description 37
- 235000000346 sugar Nutrition 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims description 96
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 23
- 239000008103 glucose Substances 0.000 claims description 23
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 16
- 239000005720 sucrose Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 8
- 229960005274 benzocaine Drugs 0.000 claims description 8
- 239000000155 melt Substances 0.000 claims description 8
- 229940041616 menthol Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 235000020374 simple syrup Nutrition 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 3
- 229960001985 dextromethorphan Drugs 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 7
- 244000166124 Eucalyptus globulus Species 0.000 claims 7
- 241000167854 Bourreria succulenta Species 0.000 claims 1
- 235000019693 cherries Nutrition 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 description 54
- 239000006188 syrup Substances 0.000 description 54
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 22
- 239000000796 flavoring agent Substances 0.000 description 20
- 235000019634 flavors Nutrition 0.000 description 20
- 235000011187 glycerol Nutrition 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000007958 cherry flavor Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000002699 waste material Substances 0.000 description 8
- 239000003651 drinking water Substances 0.000 description 7
- 235000020188 drinking water Nutrition 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000151 deposition Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 5
- 239000002156 adsorbate Substances 0.000 description 5
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 5
- 235000021552 granulated sugar Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- RVWQQCKPTVZHJM-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylbutyric acid Chemical compound CC(O)C(C)(C)C(O)=O RVWQQCKPTVZHJM-UHFFFAOYSA-N 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 239000003434 antitussive agent Substances 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229940089206 anhydrous dextrose Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
Definitions
- the present invention relates to a unit dosage form for delivering a specific dose of a liquid or semi-solid medicament and the process for manufacture thereof. More specifically, a unit dosage form has been found which comprises an edible relatively hard unitary outer shell which serves to contain the liquid or semi-solid center and enables the product to be handled and chewed or dissolved to deliver the specific medicament dose.
- the invention in its broadest aspect comprises an edible unit dosage form for delivering a medicament comprising a relatively hard unitary outer shell which is essentially comprised of a sugar which crystallizes slowly from the melt, said sugar comprising sucrose, glucose or mixtures thereof, and a liquid or semi-solid center contained within the shell comprising a dose of a medicament accurate to within about ⁇ 5% of a prescribed dosage.
- the outer shell described herein is essentially composed of sugar taken from the group of sugars comprising essentially sucrose, glucose and mixtures thereof.
- Other ingredients in the shell optionally include flavorings and/or therapeutic amounts of medicaments such as menthol-eucalyptus, benzocaine and mixtures thereof.
- the liquid or semi-solid center may include a sugar syrup, along with the medicament dose, for flavor.
- An example of the medicament may be a cough suppressant, antibiotic or other medicine in liquid or semi-solid form. Accuracy of dosage achieved permits use of the present invention with prescription drugs.
- the process for production of the edible unit dosage form of the present invention comprises the simultaneous addition of the composition comprising the outer shell and the composition comprising the liquid or semi-solid center in side by side injector alignment, into a mold wherein the liquid or semi-solid center has a moisture content equal to or below that of the shell composition and is accurately dosed to within ⁇ 5% of the prescribed dosage.
- Accurate measurement of the liquid or semi-solid medicament is provided by adjustment of the feeder which injects the components of the unit dosage form into the mold.
- Moisture content of the liquid or semi-solid center composition is reduced by heat and vacuum until it is equal to or below that of the outer shell composition. Regulation of the component moisture contents allows simultaneous injection of the components into a mold without an intermixing of the components.
- a unitary outer shell is produced by the simultaneous addition of the shell composition and the center composition.
- FIG. 1 is an elevational view of the unit dosage form of the present invention.
- FIG. 1A is a cross-sectional view of the unit dosage form through line 1--1 of FIG. 1.
- FIG. 2 is a plan view of the composition feeds of the molding machine used in the production of the present invention.
- a unit dosage form 2 of the present invention comprises a relatively hard outer shell 4 comprising essentially a sugar which crystallizes slowly from the melt, said sugar comprising sucrose, glucose or mixtures thereof and a liquid or semi-solid center 6 comprising a medicament in a therapeutic amount accurate to within ⁇ 5% of the prescribed dosage, making it suitable for dispensing prescription drugs.
- the product of the present invention comprises a form of taking medication which is easy to handle and convenient to take.
- a sugar syrup may be included in the liquid or semi-solid center composition 10 for improved flavor, which provides a pleasant taste.
- the outer molten shell composition 8 is essentially comprised of a sugar which crystallizes slowly, said sugar comprising sucrose, glucose, or mixtures thereof and optionally flavorings and therapeutic medicaments such as the anesthetic benzocaine.
- the glucose, sucrose and water are placed in an autofeed weigher of a suitable apparatus.
- a preferred apparatus is the Baker Perkins Candymolder® which is microprocessor controlled. This is described in the literature, especially in a May, 1985 publication by Baker Perkins BCS Limited, entitled Quality Candy Production, 16 pages. Further details of center-filled candymaker apparatus are given in U.K. Patent Application No. 2018668A, Oct. 24, 1979. As shown in FIG.
- This molten shell composition 8 is transferred to a microfilm buffer tank where agitation is maintained.
- the shell composition 8 is then pumped into a microfilm cooker where it flows into the "shell hoppers", which feed the shell injectors 14, by the use of a rotating cone. Flavor pumps can then be activated to provide flavor to the molten shell composition 8.
- the center composition 10 is prepared from the addition of a homogeneous medicament mix to a cooked sugar syrup mix in a vacuum cooker. Under heat and vacuum the moisture content of the center composition 10 is reduced to or below that of the molten shell composition 8. The moisture content of the center composition 10 should be about 5% H 2 O and is preferably about or less than 3% H 2 O.
- the center composition 10 is then removed from the vacuum cooker to a jacketed conditioning kettle where such optional ingredients as menthol and/or flavorings can be added.
- the center composition 10 in this form is added to the molding machine in the "center hopper" which feeds the center injector 16.
- the heated molten shell composition 8 and center composition 10 are then fed through the cylinders to the injectors and into a waste tray to be sure the system is full.
- a sample is run to weight the components and make any necessary flow adjustments. Fine tuning of the equipment allows doses of the composition to achieve accuracy to within about ⁇ 5% of the prescribed dosage.
- the separate compositions 8 and 10 are then deposited into a mold 20 simultaneously, the shell injectors 14 being placed laterally to the center injector 16 (See FIG. 2).
- the molten shell composition 8 forms in the mold around the center composition 10 in a unitary structure, encompassing the center composition 8.
- the molten unit dosage form 22 in the mold 20 is allowed to solidify and harden, whereafter it is released from the mold 20 in the finished unit dosage form 2.
- An edible cough and cold product in the unit dosage form of the present invention comprising an edible, relatively hard, unitary outer shell which comprises essentially a sugar comprising sucrose and glucose, which crystallizes slowly from the melt, and a liquid or semi-solid medicament center wherein the medicament dose is provided within about ⁇ 5% by weight of the prescribed dosage is produced.
- the outer shell comprises, along with glucose and sucrose, menthol-eucalyptus and benzocaine.
- the unitary shell encompasses a liquid or semi-solid medicament center comprising dextromethorphan as the active therapeutic medicament and a sugar syrup for flavoring.
- Step #2 Add to the vacuum cooker containing the cooked syrup (Step #2) 64.67 Kg of Premix #1 (DMHB/Glycerin). Mix, and flush tank ball valve, continue to mix syrup for 10 minutes. After 10 minutes close vacuum tank cover and begin drawing a vacuum to 22 inches for three (3) minutes. Transfer syrup to jacketed conditioning kettle and maintain syrup temperature at 45°-55° C. At 45°-55° C. add 140 gm of 1-Menthol and 1160 gm of Cherry flavor Natural and Artificial. Mix syrup slowly for 15 minutes. This syrup is ready for depositing Step 5.
- Premix #1 DMHB/Glycerin
- Activate power supply on microfilm control panel Activate hopper heaters on the control panel.
- Set outer shell hopper temperature to 135° C. and set center shell hopper to 50° C. Meter, by pump, syrup from buffer tank to BP microfilm cooker.
- Cook the syrup to 145° C. at open vacuum.
- the following steps comprise the process for producing an example product, Monarch Adult formula.
- the example is not intended to limit the invention in any manner whatsoever.
- Step #5 Discharge the syrup from cooker and adjust the rate to 3500 g/minute.
- the following steps comprise the process for producing an example product, Monarch Children's Formula.
- the example is not intended to limit the invention in any manner whatsoever.
- This syrup is ready for cooking in the microfilm cooker.
- Step #5 Discharge the syrup from cooker and adjust the rate to 2900 g/minute.
- Pump the center syrup in Step #5 into center hopper. Begin depositing the center syrup in waste tray until all cylinders are pumping. Activate the flavor incorporator and set pump at 25 rpm. Activate flavor pumps. Begin to deposit both outer shell and center in waste tray. Begin to deposit into molds.
- the medicament can comprise an antibiotic.
- benzocaine another anesthetic may be used.
- dextromethorphan another cough suppressant can be used. All such obvious variations are within the full intended scope of the appended claims.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Jellies, Jams, And Syrups (AREA)
- Confectionery (AREA)
Abstract
Description
______________________________________
(a) Glycerin USP 151.2 Kg
(b) 10% Dextromethorphan
Hydrobromide Adsorbate
76.2 Kg
______________________________________
______________________________________
(a) FD and C Red # 40
177.3 g
(b) Drinking Water 1.8 Kg
______________________________________
______________________________________
(a) Granulated Sugar
68.2 Kg
(b) Glucose Syrup 63 DE
85.1 Kg
(c) Water 27.0 Kg
______________________________________
______________________________________
(a) Granulated Sugar
68.2 Kg
(b) Glucose Syrup 63 DE
85.1 Kg
(c) Water 27.0 Kg
______________________________________
______________________________________
(d) FD and C Red # 40 10% w/w
solution 1950.3 g
______________________________________
______________________________________
(a) 10% Dextromethorphan
Hydrobromide adsorbate/
Glycerin Mix 227.9 Kg
______________________________________
______________________________________
(a) 1-Methanol 492.9 g
(b) Artifical Cherry Flavor
4088.2 g
______________________________________
______________________________________
(a) FD and C Red # 40 Dye
86.5 g
(b) Warm Drinking Water
2422.5 g
______________________________________
______________________________________
(a) 1-Methanol USP
1980.3 g
(b) Eucalyptus Oil
1980.3 g
(c) Menthyl Lactate
1980.3 g
______________________________________
______________________________________
(d) Artifical Cherry Flavor
26,264.4 g
______________________________________
Set pump rate on the flavor pump
# 2 to 54.9 g/minute
______________________________________
(a) Drinking Water
27.0 Kg
(b) Glucose HM 43DE
75.0 Kg
(c) Granulated Sugar
75.0 Kg
______________________________________
______________________________________
(a) FD and C Red #40 5% w/w
solution 150 g
(b) Benzocaine USP 395 g
______________________________________
______________________________________
B and L Pump Setting 1.8-2.0
Preheater Steam Pressure
68-70 lb./sq. in.
Discharge Pump Pressure
18-20 lb./sq. in.
Microfilm Steam Pressure
75-85 lb./sq. in.
Outlet syrup temperature
148-150° C.
Discharge Pump Setting 1.0-1.2
Phasing Setting 48
Outer Shell Volume Setting
3.4
Center Volume Setting 2.5
Strokes/Minute Setting 50
Shell Hopper Temp. Setting
135° C.
Center Hopper Temp. Setting
50° C.
Manifold Temp. Setting 145° C.
Shell Hopper Jacket Simmerstat
1
Shell Hopper Base Simmerstat
1
Manifold Heater Simmerstat
2-4
Center Hopper Simmerstat
1 or off
Center Base Simmerstat 1 or off
______________________________________
______________________________________ Target Weight 5.63 Range 5.34 g to 5.91 ______________________________________
______________________________________
(a) Glycerin USP 76.1 Kg
(b) 10% Dextromethorphan
Hydrobromide Adsorbate
38.6 Kg
______________________________________
______________________________________
(a) FD and C #40
89.3 g
(b) Drinking Water
893.0 g
______________________________________
______________________________________
(a) Granulated sugar
68.7 Kg
(b) Glucose syrup 63 DE
85.7 Kg
(c) Water 27.2 Kg
______________________________________
______________________________________
(d) FD and C Red #40 10% w/w
solution 982.3 Kg
______________________________________
______________________________________
(a) 10% Dextromethorphan
Hydrobromide adsorbate/
Glycerin Mix 114.8 Kg
______________________________________
______________________________________
(a) 1-Methanol 248.4 g
(b) Artifical Cherry Flavor
2059.5 g
______________________________________
______________________________________
(a) FD and C Red #40 dye
86.5 g
(b) Warm drinking water
2422.5 g
______________________________________
______________________________________
(a) 1-Methanol USP
1309.8 g
(b) Eucalyptus Oil
1309.8 g
______________________________________
______________________________________
(d) Artifical Cherry Flavor
23,412.0 g
______________________________________
______________________________________
(a) Drinking Water
27.0 Kg
(b) Glucose HM 43DE
75.0 Kg
(c) Granulated Sugar
75.0 Kg
______________________________________
______________________________________
(a) FD and C Red #40 w/w solution
150 g
(b) Benzocaine USP 243 g
______________________________________
______________________________________
B and L Pump Setting 1.8-2.0
Preheater Steam Pressure
68-70 lb./sq. in.
Discharge Pump Pressure
18-20 lb./sq. in.
Microfilm Steam Pressure
75-85 lb./sq. in.
Outlet syrup temperature
148-150° C.
Discharge Pump Setting 1.0-1.2
Phasing Setting 48
Outer Shell Volume Setting
3.4
Center Volume Setting 2.5
Strokes/Minute Setting 50
Shell Hopper Temp. Setting
135° C.
Center Hopper Temp. Setting
50° C.
Manifold Temp. Setting 145° C.
Shell Hopper Jacket Simmerstat
1
Shell Hopper Base Simmerstat
1
Manifold Heater Simmerstat
2-4
Center Hopper Simmerstat
1 or off
Center Base Simmerstat 1 or off
______________________________________
______________________________________ Target weight 4.17 g ______________________________________ Range 3.96 g to 4.37 g
Claims (16)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/183,683 US4929446A (en) | 1988-04-19 | 1988-04-19 | Unit dosage form |
| AU33138/89A AU616504B2 (en) | 1988-04-19 | 1989-04-18 | Novel unit dosage form |
| FR8905229A FR2630004A1 (en) | 1988-04-19 | 1989-04-19 | NEW FORM OF UNIT DOSING |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/183,683 US4929446A (en) | 1988-04-19 | 1988-04-19 | Unit dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4929446A true US4929446A (en) | 1990-05-29 |
Family
ID=22673881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/183,683 Expired - Lifetime US4929446A (en) | 1988-04-19 | 1988-04-19 | Unit dosage form |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4929446A (en) |
| AU (1) | AU616504B2 (en) |
| FR (1) | FR2630004A1 (en) |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994018954A1 (en) * | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5602178A (en) * | 1994-11-14 | 1997-02-11 | Ciba-Geigy Corporation | Bath products containing menthyl lactate |
| US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| WO2003026614A1 (en) * | 2001-09-28 | 2003-04-03 | Mcneil-Ppc, Inc. | Dosage form containing a confectionery composition |
| US20030068367A1 (en) * | 2001-09-28 | 2003-04-10 | Sowden Harry S. | Systems, methods and apparatuses for manufacturing dosage forms |
| US20030068373A1 (en) * | 2001-09-28 | 2003-04-10 | Joseph Luber | Immediate release tablet |
| US20030077319A1 (en) * | 2001-10-18 | 2003-04-24 | Huntley James Benjamin | Double-headed, closed-mouth cough suppressant and cold relief device |
| US20030086973A1 (en) * | 2001-09-28 | 2003-05-08 | Sowden Harry S | Systems, methods and apparatuses for manufacturing dosage forms |
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US20040033267A1 (en) * | 2002-03-20 | 2004-02-19 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US20040156902A1 (en) * | 2002-09-28 | 2004-08-12 | Der-Yang Lee | Composite dosage forms having an inlaid portion |
| US20040175425A1 (en) * | 2001-09-28 | 2004-09-09 | Sowden Harry S. | Systems, methods and apparatuses for manufacturing dosage forms |
| US20040247743A1 (en) * | 1997-09-18 | 2004-12-09 | Wm. Wrigley, Jr. Company | Chewing gum containing physiological cooling agents |
| US20050074514A1 (en) * | 2003-10-02 | 2005-04-07 | Anderson Oliver B. | Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms |
| US6982094B2 (en) | 2001-09-28 | 2006-01-03 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
| US20060073175A1 (en) * | 1993-02-22 | 2006-04-06 | American Bioscience, Inc. | Methods and formulations for delivery of pharmacologically active agents |
| US20060233881A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Modified release dosage form |
| US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20070248717A1 (en) * | 2004-02-26 | 2007-10-25 | Johnson Sonya S | Confections Containing a Blend of Physiological Cooling Agents |
| US20080160095A1 (en) * | 1993-02-22 | 2008-07-03 | Abraxis Bioscience, Llc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997042945A1 (en) * | 1996-05-13 | 1997-11-20 | Novartis Consumer Health S.A. | Oral pharmaceutical compositions |
| WO1998002182A1 (en) * | 1996-07-12 | 1998-01-22 | Novartis Consumer Health S.A. | Oral pharmaceutical combinations of nsaids with terpenoids |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2580683A (en) * | 1947-01-11 | 1952-01-01 | Moutsuikerindustrie & Extracti | Capsules filled with aqueous solutions and method of preparing the same |
| US4260596A (en) * | 1979-08-13 | 1981-04-07 | Bristol-Myers Company | Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same |
| US4752485A (en) * | 1984-10-05 | 1988-06-21 | Warner-Lambert Company | Novel sweetener delivery systems |
| US4753790A (en) * | 1986-12-16 | 1988-06-28 | Warner-Lambert Company | Sorbitol coated comestible and method of preparation |
-
1988
- 1988-04-19 US US07/183,683 patent/US4929446A/en not_active Expired - Lifetime
-
1989
- 1989-04-18 AU AU33138/89A patent/AU616504B2/en not_active Expired - Fee Related
- 1989-04-19 FR FR8905229A patent/FR2630004A1/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2580683A (en) * | 1947-01-11 | 1952-01-01 | Moutsuikerindustrie & Extracti | Capsules filled with aqueous solutions and method of preparing the same |
| US4260596A (en) * | 1979-08-13 | 1981-04-07 | Bristol-Myers Company | Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same |
| US4752485A (en) * | 1984-10-05 | 1988-06-21 | Warner-Lambert Company | Novel sweetener delivery systems |
| US4753790A (en) * | 1986-12-16 | 1988-06-28 | Warner-Lambert Company | Sorbitol coated comestible and method of preparation |
Cited By (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080160095A1 (en) * | 1993-02-22 | 2008-07-03 | Abraxis Bioscience, Llc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20070117862A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5498421A (en) * | 1993-02-22 | 1996-03-12 | Vivorx Pharmaceuticals, Inc. | Composition useful for in vivo delivery of biologics and methods employing same |
| AU673057B2 (en) * | 1993-02-22 | 1996-10-24 | Abraxis Bioscience, Llc | Methods for (in vivo) delivery of biologics and compositionsuseful therefor |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US20030133955A1 (en) * | 1993-02-22 | 2003-07-17 | American Bioscience, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| CN1839806B (en) * | 1993-02-22 | 2011-04-13 | 阿布拉科斯生物科学有限公司 | Methods for in vivo delivery of biologics and compositions useful therefor |
| US20070191473A1 (en) * | 1993-02-22 | 2007-08-16 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20070122468A1 (en) * | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20070122465A1 (en) * | 1993-02-22 | 2007-05-31 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US20060073175A1 (en) * | 1993-02-22 | 2006-04-06 | American Bioscience, Inc. | Methods and formulations for delivery of pharmacologically active agents |
| US20070128290A1 (en) * | 1993-02-22 | 2007-06-07 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| WO1994018954A1 (en) * | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US5602178A (en) * | 1994-11-14 | 1997-02-11 | Ciba-Geigy Corporation | Bath products containing menthyl lactate |
| US20050019445A1 (en) * | 1997-09-18 | 2005-01-27 | Wm. Wrigley Jr. Company | Chewing gum containing physiological cooling agents |
| US20080199565A1 (en) * | 1997-09-18 | 2008-08-21 | Wm. Wrigley Jr. Company | Chewing Gum Containing Physiological Cooling Agents |
| US7364761B2 (en) | 1997-09-18 | 2008-04-29 | Wm. Wrigley Jr. Company | Chewing gum containing physiological cooling agents and method of preparing |
| US20040247743A1 (en) * | 1997-09-18 | 2004-12-09 | Wm. Wrigley, Jr. Company | Chewing gum containing physiological cooling agents |
| US20070098842A1 (en) * | 1997-09-18 | 2007-05-03 | Wm. Wrigley Jr. Company | Chewing gum containing physiological cooling agents |
| US7078066B2 (en) | 1997-09-18 | 2006-07-18 | Wm. Wrigley Jr. Company | Chewing gum containing physiological cooling agents and method of making |
| US20100322853A1 (en) * | 2000-09-21 | 2010-12-23 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US20100329976A1 (en) * | 2000-09-21 | 2010-12-30 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US20070224279A1 (en) * | 2001-09-14 | 2007-09-27 | Elan Pharma International Ltd. | Stabilization of chemical compounds using nanoparticulate formulations |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| US20040062804A1 (en) * | 2001-09-28 | 2004-04-01 | Der-Yang Lee | Modified release dosage forms |
| US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
| US6982094B2 (en) | 2001-09-28 | 2006-01-03 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
| US20050147677A1 (en) * | 2001-09-28 | 2005-07-07 | Sowden Harry S. | Systems, methods and apparatuses for manufacturing dosage forms |
| US20050129763A1 (en) * | 2001-09-28 | 2005-06-16 | Sowden Harry S. | Systems, methods and apparatuses for manufacturing dosage forms |
| US7122143B2 (en) | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
| US8673190B2 (en) | 2001-09-28 | 2014-03-18 | Mcneil-Ppc, Inc. | Method for manufacturing dosage forms |
| US20060246136A1 (en) * | 2001-09-28 | 2006-11-02 | Sowden Harry S | Systems, methods and apparatuses for manufacturing dosage forms |
| US8545887B2 (en) | 2001-09-28 | 2013-10-01 | Mcneil-Ppc, Inc. | Modified release dosage forms |
| US7217381B2 (en) | 2001-09-28 | 2007-05-15 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
| US20050019376A1 (en) * | 2001-09-28 | 2005-01-27 | Mcnally Gerard P. | Dosage form containing a confectionery composition |
| US6837696B2 (en) | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
| US20040241208A1 (en) * | 2001-09-28 | 2004-12-02 | Sowden Harry S. | Fondant-based pharmaceutical composition |
| US20040175425A1 (en) * | 2001-09-28 | 2004-09-09 | Sowden Harry S. | Systems, methods and apparatuses for manufacturing dosage forms |
| US20040170750A1 (en) * | 2001-09-28 | 2004-09-02 | Bunick Frank J. | Edible composition and dosage form comprising an edible shell |
| US8114328B2 (en) | 2001-09-28 | 2012-02-14 | Mcneil-Ppc, Inc. | Method of coating a dosage form comprising a first medicant |
| US7972624B2 (en) | 2001-09-28 | 2011-07-05 | Shun-Por Li | Method of manufacturing modified release dosage forms |
| US7297345B2 (en) | 2001-09-28 | 2007-11-20 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
| US7323192B2 (en) | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| US7968120B2 (en) | 2001-09-28 | 2011-06-28 | Mcneil-Ppc, Inc. | Modified release dosage forms |
| WO2003026614A1 (en) * | 2001-09-28 | 2003-04-03 | Mcneil-Ppc, Inc. | Dosage form containing a confectionery composition |
| US20030086973A1 (en) * | 2001-09-28 | 2003-05-08 | Sowden Harry S | Systems, methods and apparatuses for manufacturing dosage forms |
| US20030068367A1 (en) * | 2001-09-28 | 2003-04-10 | Sowden Harry S. | Systems, methods and apparatuses for manufacturing dosage forms |
| US20030068373A1 (en) * | 2001-09-28 | 2003-04-10 | Joseph Luber | Immediate release tablet |
| US7635490B2 (en) | 2001-09-28 | 2009-12-22 | Mcneil-Ppc, Inc. | Modified release dosage form |
| US20090155372A1 (en) * | 2001-09-28 | 2009-06-18 | Shun-Por Li | Method of manufacturing modified release dosage forms |
| US6932978B2 (en) * | 2001-10-18 | 2005-08-23 | James Benjamin Huntley | Double-headed, closed-mouth cough suppressant and cold relief device |
| US20030077319A1 (en) * | 2001-10-18 | 2003-04-24 | Huntley James Benjamin | Double-headed, closed-mouth cough suppressant and cold relief device |
| US20080226732A1 (en) * | 2002-03-20 | 2008-09-18 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US20040033267A1 (en) * | 2002-03-20 | 2004-02-19 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US20080050461A1 (en) * | 2002-03-20 | 2008-02-28 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
| US20040156902A1 (en) * | 2002-09-28 | 2004-08-12 | Der-Yang Lee | Composite dosage forms having an inlaid portion |
| US20050074514A1 (en) * | 2003-10-02 | 2005-04-07 | Anderson Oliver B. | Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms |
| US20070248717A1 (en) * | 2004-02-26 | 2007-10-25 | Johnson Sonya S | Confections Containing a Blend of Physiological Cooling Agents |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| US20060233881A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Modified release dosage form |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3313889A (en) | 1989-10-26 |
| AU616504B2 (en) | 1991-10-31 |
| FR2630004A1 (en) | 1989-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4929446A (en) | Unit dosage form | |
| US4260596A (en) | Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same | |
| US4517205A (en) | Co-deposited two-component hard candy | |
| US7452558B2 (en) | Three-layered centerfilled gum product with candy shell | |
| EP0324072B1 (en) | Beverage capsules | |
| CN101411378A (en) | Eutrit candy lozenge and preparation method thereof | |
| CN101005766A (en) | Dual textured swirled confections | |
| US3208405A (en) | Method of making a chewing candy | |
| Peters | Medicated lozenges | |
| US4925683A (en) | Beverage capsules | |
| CN101485376A (en) | Sugar-free candy and preparation method thereof | |
| US2801922A (en) | Frozen confection | |
| CN102631289B (en) | Highly porous speed collapses solid dosage forms and comprises the preparation method who produces powder and step of freeze drying | |
| US3684528A (en) | Fast setting marshmallow type confection | |
| CN116530606A (en) | Pectin iron-rich soft sweet and preparation method thereof | |
| CN107412185A (en) | A kind of dog containing food calling composition, cat soft capsule | |
| JPH0778018B2 (en) | Method for producing a dosage unit dosage form | |
| CN107396948B (en) | Lactobacillus cake and making method thereof | |
| RU2381691C1 (en) | Method of production of toffee with filling | |
| JPH01128748A (en) | Soft candy containing center | |
| WO1998054977A1 (en) | Confection with multiple juicy regions and methods for making the same | |
| SU1268141A1 (en) | Method of producing antinicotine chewing gum | |
| US5688521A (en) | Lactulose pastilles | |
| CN115444066A (en) | A kind of candy preparation method with health care function | |
| RU2198537C2 (en) | Method of producing fondant sweets with starch-free dropping of sweets centers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: AMERICAN CYANAMID COMPANY, STAMFORD, CONNECTICUT, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BARTOLUCCI, RAYMOND A.;REEL/FRAME:004870/0550 Effective date: 19880412 Owner name: AMERICAN CYANAMID COMPANY,CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BARTOLUCCI, RAYMOND A.;REEL/FRAME:004870/0550 Effective date: 19880412 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |